Table 1.
Patient characteristics of the cohort
| Characteristic | No. of patients (%) |
|---|---|
| Age, y | |
| ≤47 | 1439 (52.5) |
| >47 | 1303 (47.5) |
| Gender | |
| Female | 792 (28.9) |
| Male | 1950 (71.1) |
| Smoking history | |
| No | 1731 (63.1) |
| Yes | 1011 (36.9) |
| NPC family history | |
| No | 2403 (87.6) |
| Yes | 340 (12.4) |
| T stageb | |
| T1 | 226 (8.2) |
| T2 | 866 (31.6) |
| T3 | 1650 (60.2) |
| N stageb | |
| N0 | 625 (8.2) |
| N1 | 1248 (31.6) |
| N2 | 869 (60.2) |
| Overall stage | |
| II | 779 (28.4) |
| III | 1963 (71.6) |
| EBV DNA levela | |
| ≤1460 copies/mL | 1554 (56.3) |
| >1460 copies/mL | 1198 (43.7) |
| Treatment method | |
| IMRT alone | 923 (33.7) |
| CCRT | 1819 (66.3) |
Pearson χ2 test was used to calculate the P‐value.
Abbreviations: CCRT, concurrent chemoradiotherapy; EBV, Epstein‐Barr virus; IMRT, intensity‐modulated radiotherapy; NPC, nasopharyngeal carcinoma.
a
The value of EBV‐DNA levels is based on receiver operating characteristic (ROC) curve analysis.
b
According to the seventh edition of UICC/AJCC staging system.